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SUMMARY
Meta-analyses of genome-wide association studies (GWAS) have identified >240 loci associated 
with type 2 diabetes (T2D)1,2, however most loci have been identified in analyses of European-
ancestry individuals. To examine T2D risk in East Asian individuals, we meta-analyzed GWAS 
data in 77,418 cases and 356,122 controls. In the main analysis, we identified 301 distinct 
association signals at 183 loci, and across T2D association models with and without consideration 
of body mass index and sex, we identified 61 loci newly implicated in T2D predisposition. 
Common variants associated with T2D in both East Asian and European populations exhibited 
strongly correlated effect sizes. New associations include signals in/near GDAP1, PTF1A, SIX3, 
ALDH2, a microRNA cluster, and genes that affect muscle and adipose differentiation3. At 
another locus, eQTLs at two overlapping T2D signals affect two genes, NKX6-3 and ANK1, in 
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different tissues4–6. Association studies in diverse populations identify additional loci and 
elucidate disease genes, biology, and pathways.
Type 2 diabetes (T2D) is a common metabolic disease primarily caused by insufficient 
insulin production and/or secretion by the pancreatic β cells and insulin resistance in 
peripheral tissues7. Most genetic loci associated with T2D have been identified in 
populations of European (EUR) ancestry, including a recent meta-analysis of genome-wide 
association studies (GWAS) of nearly 900,000 individuals of European ancestry that 
identified >240 loci influencing T2D risk1. Differences in allele frequency between 
ancestries affect the power to detect associations within a population, particularly among 
variants rare or monomorphic in one population but more frequent in another2,8. Although 
smaller than studies in European populations, a recent T2D meta-analysis in almost 200,000 
Japanese individuals identified 28 additional loci2. The relative contributions of different 
pathways to T2D pathophysiology may also differ between ancestry groups. For example, in 
East Asian (EAS) populations, T2D prevalence is greater than in European populations 
among people of similar body mass index (BMI) or waist circumference9. To identify new 
genetic associations and provide insight into T2D pathogenesis, we performed the largest 
meta-analysis of East Asian individuals to date.
RESULTS
We conducted a fixed-effect inverse-variance weighted GWAS meta-analysis combining 23 
studies imputed to the 1000 Genomes Phase 3 reference panel from the Asian Genetic 
Epidemiology Network (AGEN) consortium (Supplementary Tables 1–3). We performed 
sex-combined T2D association without BMI adjustment in 77,418 T2D cases and 356,122 
controls (effective sample size, Neff=211,793). For the subset of 54,481 T2D cases and 
224,231 controls (Neff= 135,780) with BMI available, additional analyses were performed 
with and without BMI adjustment in sex-combined and sex-stratified models (Extended Data 
Figure 1). We defined “lead” variants as the strongest T2D-associated variants with 
P<5x10−8 and defined the region +/− 500 kb from the lead variant as a locus. A locus was 
considered novel if the lead variant was located at least 500 kb from previously reported 
T2D-associated variants in any ancestry.
Using summary association statistics for ~11.8 million variants, without adjustment for BMI 
(Extended Data Figure 1; Supplementary Tables 1–3), we identified lead variants associated 
with T2D at 183 loci, of which 51 were novel (Extended Data Table 1; Extended Data 
Figure 2; Supplementary Table 4). Lead variants at all novel loci were common (MAF≥5%; 
Extended Data Figure 3), except for low-frequency variants near GDAP1 (MAF=2.4%), 
which regulates mitochondrial proteins and metabolic flux in skeletal muscle10, and PTF1A 
(MAF=4.7%), which encodes a transcription factor required for pancreatic acinar cell 
development11. Lead variants met a stricter P-value threshold for significance based on 
Bonferroni correction for 11.8 million tests (P<4.2x10−9) at 146 of the 183 loci, including 
29 of the 51 novel loci.
Using GCTA12, we identified 301 distinct association signals that met a locus-wide 
significance threshold of P<1x10−5 (Supplementary Table 5), 228 of which were genome-
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wide significant (P<5x10−8). Overall, we observed 2-4 signals at 46 loci and ≥5 signals at 12 
loci. Among the ten loci with the most significant meta-analysis P-values of association, 
seven contained ≥5 distinct signals (17 signals at INS/IGF2/KCNQ1; 7 signals at 
CDKN2A/B and GRM8/PAX4/LEP; 5 signals at CDKAL1, HHEX/IDE, CDC123/
CAMK1D, and TCF7L2; Extended Data Figure 4; Supplementary Table 5). The seven 
signals at the GRM8/PAX4/LEP locus span 1.4 Mb, and no evidence of T2D association at 
this locus has yet been reported in non-East Asian ancestry groups1,13 (Extended Data 
Figure 4C). Joint analyses confirmed independent associations (LD r2=0.0025) at two 
previously reported PAX4 missense variants14, rs2233580 [Arg192His: risk allele frequency 
(RAF)=8.6%, OR=1.31, 95% CI 1.28 – 1.34, PGCTA=3.4x10−93] and rs3824004 
(Arg192Ser: RAF=3.4%, OR=1.24, 95% CI 1.19-1.28, PGCTA=1.1x10−30). The association 
signals at this locus also include variants near LEP, which encodes leptin, a hormone that 
regulates appetite15; increased leptin levels are associated with obesity and T2D16.
At the previously reported ANK1/NKX6-3 locus1,17, we observed three distinct T2D 
association signals, two of which overlap and consist of variants spanning only ~25 kb 
(Figure 1). Given conflicting interpretation of candidate genes1,5,18, we compared the T2D-
association signals identified in East Asian individuals to eQTLs reported at this locus in 
islets1,18–20, subcutaneous adipose6, and skeletal muscle5. At the strongest signal, the lead 
T2D-associated variant rs33981001 is in high LD with the lead cis-eQTL variant for 
NKX6-3 in pancreatic islets (rs12549902; EAS LD r2=0.79, EUR r2=0.83)18, and the T2D 
risk allele is associated with decreased expression of NKX6-3 (β=−0.36, P=6.1x10−7; Figure 
1)4. NKX6-3, or NK6 homeobox 3, encodes a pancreatic islet transcription factor required 
for the development of alpha and β cells in the pancreas21 and has been shown to influence 
insulin secretion16. At the second T2D-association signal, rs62508166 is in high LD with the 
lead cis-eQTL variant for ANK1 in subcutaneous adipose tissue19 and skeletal muscle15 
(rs516946; EAS LD r2=0.96, EUR r2=0.80), and the T2D risk allele is associated with 
increased expression of ANK1 (subcutaneous adipose: β=0.20, P=1.8x10−7; skeletal muscle: 
β=1.01, P=2.8x10−22). ANK1 belongs to the ankyrin family of integral membrane proteins 
and has been shown to affect glucose uptake in skeletal muscle, and changes in its 
expression level may lead to insulin resistance22. Together, these GWAS and eQTL signals 
suggest that variants within this ~25 kb region act to increase or decrease expression levels 
of two different genes in different tissues to increase T2D risk.
In T2D association analyses adjusted for BMI, we identified an additional six loci, four of 
which were not reported previously for T2D, including loci near MYOM3/SRSF10, TSN, 
GRB10, and NID2 (Supplementary Table 4). At the NID2 locus, the T2D risk allele is very 
rare or monomorphic in non-East Asian individuals and has previously demonstrated 
significant associations with lower BMI and higher triglycerides in East Asian individuals, 
consistent with a lipodystrophy phenotype23,24. The lead GRB10 variant is in low LD (EUR 
r2=0.08, EAS r2=0.57) with a variant associated with glucose-stimulated insulin secretion in 
European individuals25.
Across the models with and without adjustment for BMI, correlation for the effect sizes 
genome-wide was higher in East Asian individuals (r=0.98) than in European individuals 
(r=0.89). For the 189 T2D-associated loci in East Asian individuals, the correlation 
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increased to 0.99 (Extended Data Figure 5). Loci with larger effects in BMI-adjusted models 
include FGFR2 and NID2, identified only in East Asian populations and associated with 
lipodystrophy traits or body fat distribution. These results may reflect the role of body fat 
distribution in insulin resistance and T2D among East Asian individuals.
In sex-stratified analyses of males (28,027 cases and 89,312 controls) and females (27,370 
cases and 135,055 controls), we identified six additional novel sex-specific loci: (i) three 
male-specific loci near FOXK1, PDE3A, and IFT81, and one female-specific locus near 
LMTK2 in models without adjustment for BMI, and (ii) one male-specific locus near 
LINC00851 and one female-specific locus near CPS1 in models with adjustment for BMI 
(Supplementary Table 6). The lead CPS1 variant rs1047891 (Thr1412Asn) has been reported 
to have a stronger effect in females than in males for cardiovascular disease and several 
blood metabolites26. Taken together, we identified a total of 61 novel loci across BMI-
unadjusted, BMI-adjusted, and sex-stratified models, of which 33 met a stricter P-value 
threshold (P<4.2x10−9).
Among all T2D-associated loci, a region spanning ~2 Mb near ALDH2 exhibited the 
strongest differences between sexes (rs12231737, Phet=2.6x10−19), with compelling 
evidence of association in males (Pmales=5.8x10−27) and no evidence for association in 
females (Pfemales=0.19) (Extended Data Figure 6; Supplementary Table 6). This sex 
difference is also observed after adjusting for BMI (Pmales_adjBMI=5.2x10−21, 
Pfemales_adjBMI=0.053). Further, joint conditional analyses revealed two conditionally 
distinct signals (rs12231737, PGCTA=1.7x10−21; rs557597782, PGCTA=4.9x10−7) in males 
only. ALDH2 encodes aldehyde dehydrogenase 2 family member, a key enzyme in alcohol 
metabolism that converts acetaldehyde into acetic acid. This stretch of T2D associations in 
males reflects a long LD block that arose due to a recent selective sweep in East Asian 
individuals and results in flushing, nausea, and headache following alcohol consumption27. 
The most significantly associated missense variant in moderate LD with rs12231737 
(r2=0.68) was rs671 (ALDH2 Glu504Lys: RAF=77.7%, OR=1.17, 95% CI 1.14 – 1.20, 
Pmales=1.5x10−24), which leads to reduced ALDH2 activity and reduced alcohol 
metabolism, and has been associated with cardiometabolic traits in East Asian populations. 
The T2D risk allele is associated with better tolerance for alcohol; increased BMI, blood 
pressure, and high-density lipoprotein cholesterol; and decreased low-density lipoprotein 
cholesterol and cardiovascular risk28–30. The strong sexual dimorphism observed at this 
locus may be due to differences in alcohol consumption patterns between males and 
females28,30, effects of alcohol on BMI, and/or differences in the effect of alcohol on insulin 
sensitivity31.
With an effective sample size comparable to the largest study of T2D in European 
individuals (East Asian Neff=211,793; European Neff = 231,436)1 and imputation to a dense 
1000 Genomes reference panel, our results provide the most comprehensive and precise 
catalogue of East Asian T2D effects to date for comparisons across ancestries (Figure 2; 
Supplementary Table 7). For 183 EAS T2D loci and 231 EUR T2D loci (unadjusted for 
BMI)1, we compared the per-allele effect sizes for the 332 variants available in both datasets 
(i.e. polymorphic and passed quality control), including lead variants from both ancestries at 
shared signals. Overall, the per-allele effect sizes between the two ancestries were 
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moderately correlated (r=0.55; Figure 2A). When the comparison was restricted to the 278 
variants that are common (MAF≥5%) in both ancestries, the effect size correlation increased 
to r=0.59 (Figure 2B; Extended Data Figure 7). This effect size correlation further increased 
to r=0.87 for 106 variants significantly associated with T2D (P<5x10−8) in both ancestries. 
Based on Cochran’s heterogeneity test, 28 of 332 variants (8.4%) exhibited significant 
heterogeneity in effect sizes between East Asian and European populations, including 22 
that were significant in only one population (Supplementary Table 7) and six with larger 
effect sizes in one population (e.g. CDKAL1, KCNQ1, and HNF1B). While the overall 
effect sizes for all 332 variants appear, on average, to be stronger in East Asian individuals 
than European individuals, this trend is reduced when each locus is represented only by the 
lead variant from one population (Extended Data Figure 8). Specifically, 39 variants 
identified in the European meta-analysis with imputation using the Haplotype Reference 
Consortium panel are missing from the comparison because they were rare/monomorphic or 
poorly imputed in the East Asian meta-analysis, with imputation based on the smaller and 
more heterogenous 1000 Genomes reference panel.
Variants exhibiting the largest differences in effect sizes across ancestries are generally rare 
(MAF ≤0.1%) in European populations but common (e.g. PAX4, RANBP3L) or low-
frequency (e.g. ZNF257, DGKD) in East Asian populations. For example, rs142395395 near 
ZNF257 (RAF=96.9%, OR=1.24, 95% CI 1.19-1.29, P=7.0x10−23) has been reported only 
twice in 15,414 individuals of non-Finnish European ancestry from the gnomAD database32. 
This variant tags a previously described inversion of 415 kb observed only in East Asian 
individuals that disrupts the coding sequence and expression of ZNF257, as well as 
lymphoblastoid expression of 81 downstream genes and transcripts33. These data suggest 
that ZNF257 and/or downstream target genes influence T2D susceptibility.
We identified many loci for which the lead variants exhibited similar allele frequencies and 
effect sizes in both the East Asian and European meta-analyses, but only reached genome-
wide significance in the East Asian meta-analysis. Given shared susceptibility across 
ancestry groups, these loci may be detected in non-East Asian populations when sample 
sizes increase. Among these variants is rs117624659, located near NKX6-1 (PEAS = 
2.0x10−16, PEUR =2.2x10−4). This lead variant overlaps a highly conserved region that 
shows open chromatin specific to pancreatic islets. We conducted transcriptional reporter 
assays in MIN6 mouse insulinoma cells and observed that rs117624659 exhibited significant 
allelic differences in enhancer activity (Figure 3). In the pancreas, NK6 homeobox 1 
(NKX6.1) is required for the development of insulin-producing β cells and is a potent 
bifunctional transcriptional regulator34. Further, inactivation of Nkx6.1 in mice 
demonstrated rapid-onset diabetes due to defects in insulin biosynthesis and secretion35. 
Unexpectedly, the T2D risk allele showed increased transcriptional activity, suggesting that 
the variant does not act in isolation or that NXK6-1 is not the target gene.
At one of the novel T2D-associated loci near SIX3, the risk allele of East Asian lead variant 
rs12712928-C (RAF=40.2%, OR=1.06, 95% CI 1.04 – 1.07, P=1.8x10−14) is common 
across non-East Asian ancestries, ranging from 16.0% in Europeans to 26.4% in South 
Asians; however, there was no evidence of association in the other ancestry groups (meta-
analysis: OR=0.98, 95% CI 0.96 – 0.99, P=2.9x10−3; Extended Data Figure 9A, 
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Supplementary Table 8). Within the East Asian meta-analysis, the direction of effect is 
consistent across East Asian countries (Extended Data Figure 9B) and within the 
contributing cohorts (Extended Data Figure 9C). The T2D risk allele rs12712928-C is 
associated with higher fasting glucose levels in East Asian populations, has the strongest 
association with lower expression levels of both SIX3 and SIX2 in pancreatic islets19, and 
demonstrated allele-specific binding to the transcription factor GABPA and significantly 
lower levels of transcriptional activity36. While rs12712928-C is present on only one 
common haplotype in most populations, it is present on an additional common haplotype 
(frequency =0.075) in East Asians, suggesting that the effect size attributed to rs12712928 
may be influenced by other nearby unknown variants.
To identify potential candidate genes underlying the T2D-association signals identified in 
East Asian individuals, we further characterized 92 known and novel loci for which the lead 
variant at the primary East Asian association signal is located >500 kb from the lead variant 
of any European T2D association signal2 (Supplementary Table 9). We characterized loci 
using prior trait associations, cis-regulatory effects on expression (colocalized eQTL), 
predicted effects on protein sequence, and a literature search (Supplementary Tables 10–13). 
Based on association results from cardiometabolic trait consortia37, Biobank Japan38, and 
the UK Biobank39, the lead T2D-associated variant at 18 of the 88 loci was associated 
(P<5x10−8) with at least one additional cardiometabolic trait, most frequently BMI or a fat 
mass trait (15 loci; Supplementary Tables 10 and 12). At 12 of the examined loci, T2D 
signals were colocalized with cis-eQTLs for transcripts in subcutaneous adipose tissue 
(n=5), skeletal muscle (n=3), pancreas (n=2), islets (n=3), or blood (n=5; Supplementary 
Tables 11–12), generating hypotheses of target genes and directions of effect; further 
examination of these candidate genes is warranted. At 19 loci, the lead T2D-associated 
variant or a proxy (East Asian r2>0.80) alter the protein sequence (Supplementary Tables 
12). These variants affect mesenchymal stem cell differentiation and adipogenesis (GIT2, 
STEAP2 and JMJD1C), muscle stem cell biology (CALCR), glucose metabolism (PGM1 
and SCTR), and insulin secretion (FGFR4; Supplementary Table 13). At SCTR, which 
encodes the G-protein coupled secretin receptor, the lead variant encodes Ala122Pro, located 
in the hormone receptor domain. While mechanistic inference is required, these potential 
molecular mechanisms suggest new T2D susceptibility genes primarily detected by analyses 
in East Asian individuals.
T2D loci were also identified at clusters of noncoding RNAs with roles in islet β cell 
function. One locus includes a set of microRNAs specifically expressed in islet β cells, the 
maternally expressed noncoding RNA MEG3, and the paternally expressed gene DLK1. 
Targets of these microRNAs increase β cell apoptosis40, and reduced Meg3 impairs insulin 
secretion41. DLK1 inhibits adipocyte differentiation, protecting from obesity3, and promotes 
pancreatic ductal cell differentiation into β cells, increasing insulin secretion42,43. Other 
variants near MEG3 have been associated with type 1 diabetes (EAS and EUR LD r2=0 with 
EAS lead variant)44. The other noncoding RNA locus is the MIR17HG cluster of miRNAs 
that regulate glucose-stimulated insulin secretion and pancreatic β cell proliferation stress45; 
one of these microRNAs, miR-19a, affects hepatic gluconeogenesis46. Yet another T2D 
locus is located near TRAF3, which is a direct target of the MIR17HG microRNA cluster 
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and promotes hyperglycemia by increasing hepatic glucose production47,48. The T2D 
association results suggest that these noncoding RNAs influence disease susceptibility.
DISCUSSION
These T2D GWAS meta-analyses in the largest number of East Asian individuals analyzed 
to date identified 61 novel loci, providing additional insight into the biological basis of T2D. 
The results emphasize substantial shared T2D susceptibility with European individuals, as 
shown by the strong correlation of effect sizes among T2D-associated genetic variants with 
common allele frequencies in both East Asian and European ancestry populations. 
Compared to a recent T2D study in individuals of European ancestry1, we observed less 
attenuation of effects on T2D in analyses adjusted for BMI. Loci with a greater effect on 
T2D after adjusting for BMI include loci with lipodystrophy-like traits identified only in 
East Asian individuals to date, adding support to the observation49,50 that factors beyond 
overall BMI, such as visceral adiposity or lipodystrophy, may also play a role in T2D in East 
Asians. The results also detect novel associations in East Asian individuals identified 
because they have higher allele frequencies in East Asian populations, exhibit larger effect 
sizes, and/or are influenced by other environmental or behavioral factors such as alcohol 
consumption.
The identified loci point to multiple plausible molecular mechanisms and many new 
candidate genes linking T2D susceptibility to diverse biological processes. Following the 
annotation of loci identified in the East Asian meta-analysis, we speculate a substantial role 
for insulin resistance in T2D pathogenesis among East Asian individuals through skeletal 
muscle, adipose, and liver development and function. We also provide evidence that multiple 
distinct association signals in the same region do not necessarily act through the same gene. 
Conditionally distinct association signals in close proximity can affect different genes that 
may act in different tissues by different mechanisms, emphasizing the value of identifying 
functional variants that enable variant-to-gene links to be examined directly. Our results 
provide a foundation for future biological research in T2D pathogenesis and offer potential 
targets for mechanisms for interventions in disease risk.
METHODS
Ethics statement
All human research was approved by the relevant institutional review boards for each study 
at their respective sites (Supplementary Table 1) and conducted according to the Declaration 
of Helsinki. All participants provided written informed consent.
Study cohorts and quality control
The East Asian type 2 diabetes (T2D) meta-analyses were performed with studies 
participating in the Asian Genetic Epidemiology Network (AGEN), a consortium of genetic 
epidemiology studies of T2D and related traits conducted in individuals of East Asian 
ancestry, and the Diabetes Meta-analysis of Trans-ethnic Association Studies 
(DIAMANTE), a consortium examining the genetic contribution to T2D across diverse 
ancestry populations including African-American, East Asian, European, Hispanic, and 
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South Asian. The East Asian meta-analysis included 77,418 T2D cases and 356,122 controls 
from 23 GWAS, including three biobanks, CKB, KBA51,52, and BBJ2 [effective sample size 
(Neff) = 211,793; Extended Data Figure 1]. A subset of studies with BMI measurement 
available was analyzed with and without BMI adjustment in sex-combined and sex-specific 
models (54,481 cases, 224,231 controls; Neff = 135,780). For each study, T2D case control 
ascertainment is described in Supplementary Table 1 and summary statistics are provided in 
Supplementary Table 2. As T2D case definitions across cohorts differ, it is possible that 
cases of type 1 diabetes and maturity onset diabetes of the young (MODY) are included in 
these meta-analyses. Included studies were genotyped on either commercially available or 
customized Affymetrix or Illumina genome-wide genotyping arrays. Array quality control 
criteria implemented within each study, including variant call rate and Hardy-Weinberg 
equilibrium, are summarized in Supplementary Table 3. To harmonize study-level genotype 
scaffold for imputation to 1000 Genomes (1000G) reference panels, each study adopted a 
uniform protocol for pre-imputation quality checks. Each study applied the protocol to 
exclude variants with: i) mismatched chromosomal positions or alleles not present in the 
reference panel; ii) ambiguous alleles (AT/CG) with minor allele frequency (MAF) >40% in 
the reference panel; or iii) absolute allele frequency differences >20% compared to East 
Asian-specific allele frequencies. The genotype scaffold for each study was then imputed to 
the 1000G Phase 1 or 3 reference panel53 using minimac354 or IMPUTEv255. In BMI-
unadjusted analyses, all studies were imputed to 1000G Phase 3. In BMI-adjusted and sex-
stratified analyses, all studies were imputed to 1000G Phase 3 except for a subset of Biobank 
Japan17, which was imputed to the 1000G Phase 1 reference panel.
Study-level association analyses
Within each study, all variants were tested for association with T2D assuming an additive 
model of inheritance within a regression framework, including age, sex, and other study-
specific covariates (Supplementary Table 3). To account for population structure and 
relatedness, association analyses were either performed using FIRTH56 or mach2dat with 
additional adjustment for principal components in unrelated individuals or a linear mixed 
model with kinship matrix implemented in BOLT-LMM57. In studies analyzed with the 
linear mixed model, allelic effects and standard errors were converted to the log-odds scale 
that accounts for case-control imbalance58. Within each study, variants were removed if i) 
imputation quality score was poor (minimac3 r2<0.30; IMPUTE2 info score <0.40); ii) 
combined case control minor allele count <5; or iii) standard error of the log-OR>10. For a 
subset of the studies, BMI was added as an additional covariate, and association analyses 
were also performed separately in males and females. For each study and model, association 
statistics were corrected with genomic control inflation factor59 calculated from common 
variants (MAF≥5%) (Supplementary Table 3). For BBJ, we applied the genomic control 
inflation factor 1.21 as reported2.
Sex-combined meta-analysis
We combined study-level association statistics using fixed-effects meta-analysis with 
inverse-variance weighting of log-ORs implemented in METAL60. Variants with allele 
frequency differences >20% between 1000G Phase 1 and 3 panels were excluded from the 
meta-analysis. To assess excess inflation arising from cryptic relatedness and population 
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structure, we applied LD score regression to the meta-analysis summary statistics to estimate 
residual inflation of summary statistics, using a set of 1,889 unrelated Chinese individuals 
from the Singapore Chinese Eye Study61. The LD score regression intercepts were 0.993 for 
BMI-unadjusted, and 1.0163 for BMI-adjusted models. As the LD score regression 
intercepts indicated absence of excess inflation, the meta-analysis results were corrected for 
inflation using these LD score regression intercepts. For subsequent analyses, we considered 
only variants that were present in at least 50% of the effective sample size Neff [computed as 
4/(1/Ncases + 1/Ncontrols)]60. Heterogeneity in allelic effect sizes between studies were 
assessed with fixed-effects inverse-variance weighted meta-analysis Phet. We further 
compared the genetic effects from BMI-unadjusted and BMI-adjusted models using fixed-
effects inverse-variance weighted meta-analysis Phet. Loci were defined as novel if the lead 
variant is: (1) at least 500 kb away and confirmed by GCTA to be conditionally independent 
from previously reported T2D-associated variants in any ancestry, and (2) assessed using 
LocusZoom plots and detailed literature review to be away from known loci with extended 
LD. Lead variants mapping to loci already associated with other glycemic traits were still 
considered novel for the association with T2D.
BMI adjustment analyses and effect size comparison
For the subset of studies with both BMI-unadjusted and BMI-adjusted models, we compared 
the effect sizes and heterogeneity of the lead variants using the standardized mean difference 
to account for the correlation between the two models1. We calculated the Pearson 
correlation coefficient between effect sizes from the BMI-unadjusted and BMI-adjusted 
models for all 13.2M variants genome-wide (r=0.98) and for the lead variants at 189 T2D-
associated loci (r=0.99).
Sex-differentiated meta-analysis
The meta-analyses described above were repeated for males and females separately. The 
male-specific meta-analyses included up to 28,027 cases and 89,312 controls (Neff = 65,660) 
and the female-specific analyses included up to 27,370 cases and 135,055 controls (Neff = 
70,332). LD score regression intercepts were 1.0044 for BMI-unadjusted and 1.0045 for 
BMI-adjusted models in males and 1.0050 for BMI-unadjusted and 1.0187 for BMI-adjusted 
models in females. We further performed a test for heterogeneity in allelic effects between 
males and females as implemented in GWAMA62,63.
Detection of distinct association signals
To detect multiple distinct association signals at each associated locus, we combined 
overlapping loci when the distance between any pair of lead variants was <1 Mb. We then 
performed approximate conditional analyses using GCTA12 with genome-wide meta-
analysis summary statistics and LD estimated from 78,000 samples from the Korean 
Biobank Array52. We note the limitations in using a single population reference panel for 
LD estimation for a meta-analysis of diverse East Asian populations. We present all distinct 
signals at conditional threshold of P<1x10−5, but we suggest that readers exhibit caution and 
limit inferences from these analyses to signals that show the strongest evidence of 
association.
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Comparing loci effects between East Asian and European populations
We compared the per-allele effect sizes of lead variants identified from the East Asian BMI-
unadjusted sex-combined meta-analysis (183 lead variants) and European BMI-unadjusted 
sex-combined meta-analysis1 (231 lead variants; Supplementary Table 7). Across the 414 
associated variants from the two ancestries, 12 lead variants overlapped, resulting in 402 
unique variants. As the variants in the European analysis were imputed using the Haplotype 
Reference Consortium reference panel and did not include indel variants, a variant in strong 
LD (East Asian r2>0.90) with the lead East Asian variant was used when the lead variant 
was an indel, when possible. If the lead East Asian variant or a variant in strong LD (East 
Asian r2>0.90) was not available in the European data from DIAMANTE, we used results 
from a previous European type 2 diabetes meta-analysis64. The effect size comparison plot 
was restricted to 332 variants where data was available for both ancestries (Figure 2A). For 
loci that were significant in both the East Asian and European meta-analyses, if the lead 
variants were different, both lead variants were plotted (see Supplementary Table 7). Effect 
size plots were further restricted to: i) 278 lead variants with MAF≥5% in both East Asian 
and European meta-analyses (Extended Data Figure 7); ii) 203 lead variants significant in 
the East Asian meta-analysis (Extended Data Figure 8A); and iii) 234 lead variants 
significant in the European meta-analysis (Extended Data Figure 8B). Differences in effect 
sizes between the two populations could be due to differences in imputation quality with 
different reference panels.
Associations with other metabolic traits and outcomes
We examined publicly available GWAS summary statistics (mostly available through the 
Type 2 Diabetes Knowledge Portal37) to explore associations of the lead variant at the 92 
loci for which there are no genome-wide significant European variants within 500 kb (listed 
in Supplementary Table 9). Association statistics from the following consortia were 
available for query on the portal (last accessed August 28, 2019): coronary artery disease 
from CARDIoGRAM65, BMI and waist-hip-ratio from GIANT66,67, lipid traits from 
GLGC68, and glycemic traits from MAGIC69–73. Additionally, we used available data from 
AGEN East Asian meta-analyses for lipids74, along with the phenotypic data from the UK 
Biobank75, BioBank Japan24,38, and blood pressure data from ICBP76. For this analysis, we 
looked up the effect size and P-value of the East Asian lead variants in the other datasets. If 
the variant-trait association reached at least nominal significance (P<1x10−3), we included 
the lookup results in Supplementary Table 10. When the lead East Asian variant was missing 
in the prior GWAS data, we reported it as “NF” (not found) in the table.
Colocalization with expression quantitative trait loci (eQTL)
We searched publicly available eQTL databases such as GTEx v777 and the Parker lab Islet 
Browser19, to identify cis-eQTLs at the novel loci in adipose (subcutaneous and visceral), 
blood, pancreas, pancreatic islet, and skeletal muscle tissue. We also searched for cis-eQTLs 
in subcutaneous adipose tissue data from the METSIM study6, whole blood78, and 
peripheral blood (BioBank Japan; http://jenger.riken.jp/en/result). Colocalized eQTLs were 
identified if the lead expression level-associated variant and the GWAS lead variant were in 
high LD (r2>0.80) in Europeans to accommodate the predominantly European eQTL data. 
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Reciprocal conditional analyses were also performed using the METSIM data to determine 
if the GWAS lead variant and the lead expression-associated variant were part of the same 
eQTL signal.
Literature review
We conducted a traditional literature review to identify candidate genes at each novel locus 
using NCBI Entrez Gene, PubMed and OMIM. We included gene symbols and the following 
keywords as search terms in PubMed: diabetes, glucose, insulin, islet, adipose, muscle, liver, 
obesity. A gene was considered a potential candidate if an apparent link to T2D biology 
existed based on prior studies of gene function.
Functional annotation and experimentation at NKX6-1
We used ENCODE79, ChromHMM80, and Human Epigenome Atlas81 data available 
through the UCSC Genome Browser to identify candidate variants at the association signal 
near NKX6-1 that overlapped open-chromatin peaks, ChromHMM chromatin states, and 
chromatin-immunoprecipitation sequencing (ChIP-seq) peaks of histone modifications 
H4K4me1, H3K4me3, and H3K27ac, and transcription factors in the pancreas and 
pancreatic islets. MIN6 mouse insulinoma cells (FROM ATCC)82 were cultured in DMEM 
(Sigma) supplemented with 10% FBS, 1mM sodium pyruvate, and 0.1 mM beta-
mercaptoethanol. The cell cultures were maintained at 37° C with 5% CO2. To measure 
variant allelic differences in enhancer activity at the NKX6-1 locus, we designed 
oligonucleotide primers (forward: CCCTAGTAATGCCCTTTTTGTT; reverse: 
TCAGCCTGAGAAGTCTGTGA) with KpnI and Xhol restriction sites, and amplified the 
400-bp DNA region (GRCh37/hg19 -chr4: 85,339,430-85,339,829) around rs117624659. As 
previously described80, we ligated amplified DNA from individuals homozygous for each 
allele into the multiple cloning site of the pGL4.23 (Promega) minimal promoter luciferase 
reporter vector in both the forward and reverse orientations with respect to the genome. 
Clones were isolated and sequenced for genotype and fidelity. 2.1x105 MIN6 cells were 
seeded per well and grown to 90% confluence in 24-well plates. We co-transfected five 
independent luciferase constructs and Renilla control reporter vector (phRL-TK, Promega) 
using Lipofectamine 2000 (Life Technologies) and incubated. 48-hours post-transfection, 
the cells were lysed with Passive Lysis Buffer (Promega). Luciferase activity was measured 
using the Dual-luciferase Reporter Assay System (Promega) per manufacturer instructions 
and as previously described83. MIN6 cell lines were authenticated through genotyping and 
tested negative for mycoplasma contamination.
Extended Data
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Extended Data Figure 1: 
Flow chart of study design, depicting the different data analyses performed.
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Extended Data Figure 2: Manhattan plot for East Asian T2D meta-analysis association results in 
model unadjusted for BMI.
−log10(P) values from two-sided fixed-effects inverse-variance genome-wide meta-analysis 
association results for each variant (y-axis; maximal Neff=211,793) was plotted against the 
genomic position (hg19; x-axis). Known T2D loci achieving genome-wide significance 
(P<5.0x10−8) meta-analysis are shown in blue. Loci achieving genome-wide significance 
that are previously unreported for T2D association are shown in red.
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Extended Data Figure 3: The relationship between effect size and minor allele frequency.
Odds ratios (y-axis) and minor allele frequencies (x-axis) for 189 primary association 
signals from the T2D BMI-unadjusted models. Odds ratios are from two-sided fixed-effects 
inverse-variance meta-analysis on a maximal effective sample size of 211,793.
Spracklen et al. Page 14













Extended Data Figure 4: Regional association plots at three T2D-associated loci with the 
strongest association P-value and more than five distinct association signals in East Asians.
(A) INS/IGF2/KCNQ1, (B) CDKN2A/B, (C) PAX4/LEP. −log10(P) values were from the 
two-sided fixed-effect inverse-variance meta-analysis. Distinct signals (P<1.0x10−6 from 
GCTA conditional analyses) were plotted; Neff for each distinct signal are reported in 
Supplementary Table 4. Variants are colored based on East Asian 1000G Phase 3 LD with 
the lead variants for each association signal, shown as diamonds.
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Extended Data Figure 5: Effect size comparison of lead variants in sex-combined models 
unadjusted and adjusted for BMI.
At 189 lead variants identified in the East Asian BMI-unadjusted sex-combined T2D meta-
analysis, per-allele effect sizes (β) from the BMI-adjusted sex-combined model were plotted 
against the BMI-unadjusted sex-combined model. Both sex-combined models were from 
two-sided fixed-effect inverse-variance meta-analyses and included the same set of studies 
for comparable sample size. Each point denotes the per-allele effect size; standard errors of 
the effect size estimates extend out as grey lines. Effect sizes between the two models are 
highly correlated with a Pearson correlation coefficient r=0.99 (Supplementary Table 4).
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Extended Data Figure 6: Regional plots of male-specific T2D-associated locus, ALDH2.
For each plot, −log10(P) values from association results from two-sided fixed-effect inverse-
variance meta-analyses for each variant (y-axis) was plotted against the genomic position 
(hg19; x-axis). The lead variant rs12231737 plotted is the lead variant from the BMI-
unadjusted male-specific meta-analysis (Neff=65,202) and also the sex-combined meta-
analysis (Neff=138,947) from the same subset of individuals included in the sex-stratified 
analyses (female-specific Neff=70,051). This lead variant rs12231737 is in high LD with 
rs77768175, identified from the larger BMI-unadjusted sex-combined meta-analysis (East 
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Asian r2=0.80). (A) Males only, (B) sex-combined, and (C) females only. Variants are 
shaded based on East Asian 1000G Phase 3 LD with the lead variant, shown as a purple 
diamond.
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Extended Data Figure 7: Effect size comparison of common lead variants (MAF≥5%) identified 
in this East Asian meta-analysis and a previously published European T2D GWAS meta-
analysis2.
For 278 unique lead variants with MAF≥5% in both the East Asian and European BMI-
unadjusted meta-analyses, per-allele effect sizes (β) from Mahajan et al.2 (y-axis) were 
plotted against per-allele effect sizes from this East Asian meta-analysis (x-axis). Effect 
sizes from both meta-analyses were from two-sided fixed-effect inverse-variance meta-
analyses (maximal Neff=211,793 for East Asian and 231,436 for European meta-analyses). 
Each point denotes the per-allele effect size; standard errors of the effect size estimates 
extend out as grey lines. Variants are colored purple if they were significant in the East 
Asian meta-analysis only, green if they were significant in European meta-analysis only, and 
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blue if they were significant in both the East Asian and European meta-analyses. (see 
Methods and Supplementary Table 7).
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Extended Data Figure 8: Effect size comparison of lead variants identified in East Asian BMI-
unadjusted meta-analysis and previously published European T2D GWAS meta-analysis2.
For 332 lead variants identified from the two BMI-unadjusted meta-analyses, per-allele 
effect sizes (β) from a European meta-analysis (y-axis) were plotted against per-allele effect 
sizes from this East Asian meta-analysis (x-axis). Effect sizes from both meta-analyses were 
from two-sided fixed-effect inverse-variance meta-analysis (maximal Neff=211,793 for East 
Asian and 231,436 for European meta-analyses). Each point denotes the per-allele effect 
size; standard errors of the effect size estimates extend out as grey lines. (A) 152 lead 
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variants significant in the East Asian meta-analysis (purple) or both the East Asian and 
European meta-analysis (blue) and (B) 192 lead variants significant in the European meta-
analysis (green) or both the East Asian and European meta-analysis (blue). These plots 
include only one variant per locus, in contrast to Figure 2 and Extended Data Figure 7.
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Extended Data Figure 9: Forest plots of BMI-unadjusted meta-analysis association results at 
SIX3-SIX2 locus.
Odds ratios (black boxes) and 95% confidence intervals (horizontal lines extending out) for 
T2D associations at the lead East Asian variant (rs12712928) are presented (A) across 
ancestries of African-American (AFR), East Asian (EAS), European (EUR)2, Hispanic 
(HIS), and South Asian (SAS) individuals, (B) within four major East Asian populations 
(Chinese, Japanese, Korean, and Malay/Filipino combined due to small sample sizes), (C) 
from each contributing cohort. Effect sizes from East Asian study, ancestry, population, and 
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combined meta-analysis were from two-sided fixed-effect inverse-variance meta-analysis. 
The size of the box is proportional to the sample size of each contributing study/ancestry/
population, which are available in Supplementary Table 8. This East Asian study had >90% 
power to detect the observed association with a MAF=0.40, OR=1.06, and 77,418 T2D 
cases. Given the number of T2D cases and frequency of rs12712928-C within the other 
datasets, at 80% power, we can reasonably exclude association OR >1.07 in EUR and >1.15 
in AFR, HIS, and SAS between rs12782928 and T2D. Full study names can be found in 
Supplementary Table 1 and corresponding sample sizes can be found in Supplementary 
Table 2.
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Figure 1: Two distinct T2D-association signals at the ANK1-NKX6-3 locus associated with 
expression levels of two transcripts in two tissues.
(A) Regional association plot for East Asian sex-combined BMI-unadjusted two-sided fixed-
effect inverse-variance meta-analysis at ANK1-NKX6-3 locus. Approximate conditional 
analysis using GTCA identified three distinct T2D-association signals (P<1x10−5) at this 
locus (signal 1, rs33981001, Neff=211,793; signal 2, rs62508166, Neff=211,793; signal 3, 
rs144239281, Neff=208,431, in order of strength of association). Using 1000G Phase3 East 
Asian LD, variants are colored in red and blue with the first and second distinct signals 
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respectively (lead variants represented as diamonds). (B) Variant rs12549902, in high LD 
(EAS LD r2=0.80, EUR r2=0.83) with T2D signal 1, shows the strongest association with 
expression levels of NXK6-3 in pancreatic islets in 118 individuals16. (C) Variant rs516946, 
in high LD (EAS LD r2=0.96, EUR r2=0.80) with T2D signal 2, shows the strongest 
association with expression levels of ANK1 in subcutaneous adipose tissue in 770 
individuals19. As rs62508166 is not available in the subcutaneous adipose tissue data set, a 
variant in perfect LD (rs28591316) was used and is represented by the blue diamond.
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Figure 2: Effect size comparison of lead variants identified in this East Asian T2D GWAS BMI-
unadjusted meta-analysis and previous European T2D GWAS meta-analysis2.
For 332 unique lead variants identified from the two BMI unadjusted meta-analyses, per-
allele effect sizes (β) from the European meta-analysis (y-axis) were plotted against per-
allele effect sizes from this East Asian meta-analysis (x-axis). Effect sizes from both meta-
analyses were from two-sided fixed-effect inverse-variance meta-analysis (maximal 
Neff=211,793 for East Asian and 231,436 for European meta-analyses). Each point denotes 
the per-allele effect size; standard errors of the effect size estimates extend out as grey lines. 
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(A) All 332 lead variants; (B) 278 lead variants with minor allele frequency ≥5% in both 
ancestries. Variants are colored purple if they were significant (P<5x10−8) in the East Asian 
analysis only, green if they were significant in European analysis only, and blue if they were 
significant in both the East Asian and European analyses (see Methods and Supplementary 
Table 7). The dashed diagonal line represents the trend line across all plotted variants. 
Compared to Supplementary Table 7, 70 variants are not plotted; 31 variants were present 
only in the analysis of East Asian individuals (median effect size 0.065; interquartile range 
0.049-0.110) and 39 variants were present only in the analysis of European individuals 
(median effect size 0.083; interquartile range 0.063-0.170).
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Figure 3: rs117624659 at NKX6-1 locus exhibits allelic differences in transcriptional activity.
(A) rs117624659 (Neff=211,214; purple diamond) shows the strongest association with T2D 
in the region. P values were from two-sided fixed-effect inverse-variance meta-analysis. 
Variants are colored based on 1000G Phase 3 East Asian LD with rs117624659. (B) 
rs117624659 and an additional candidate variant rs142390274 in high pairwise LD (r2>0.80) 
span a 22 kb region approximately 75 kb upstream of NKX6-1. rs117624659 overlaps a 
region of open chromatin in pancreatic islets and lies within a region conserved across 
vertebrates. (C) rs117624659-T, associated with increased risk of T2D, showed greater 
transcriptional activity in an element cloned in both forward and reverse orientations with 
respect to NKX6-1 in MIN6 cells compared to rs117624659-C and an “empty vector” 
containing a minimal promoter. Black lines represent mean (center horizontal line) and 
standard error (extended lines) relative luciferase activity from two-sided, unpaired t-tests 
using data from n=5 biologically independent samples/independent experiments.
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